Eli Lilly and Company (NYSE:LLY) Holdings Increased by AIA Group Ltd

AIA Group Ltd grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,719 shares of the company’s stock after buying an additional 467 shares during the quarter. AIA Group Ltd’s holdings in Eli Lilly and Company were worth $10,329,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Retirement Group LLC raised its holdings in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares in the last quarter. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $35,000. Finally, Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 0.8 %

LLY stock traded down $5.95 during trading hours on Thursday, hitting $744.82. The company’s stock had a trading volume of 1,123,707 shares, compared to its average volume of 3,059,505. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $707.70 billion, a PE ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78. The stock has a 50 day moving average price of $764.03 and a two-hundred day moving average price of $657.67.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on LLY shares. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.